Pet companies lean harder on share buybacks
Bottom line
Share buybacks are becoming a more visible part of capital allocation across publicly traded pet companies, as management teams look beyond dividends to return cash to investors. GlobalPETS reported that, across 14 listed pet-related companies, dividend growth still leads, but more companies are now launching or expanding repurchase programs. Recent company actions support that trend: Central Garden & Pet increased its stock repurchase authorization by $100 million in February 2026, saying management viewed the shares as undervalued, while Freshpet authorized a new $150 million buyback in May 2026 and said it had the flexibility to return capital while continuing to invest in growth. Zoetis, the largest listed animal health company, has also emphasized buybacks alongside dividends within its broader capital allocation strategy. (ir.central.com)
Why it matters: For veterinary professionals, this is a financial story with operational implications. Buybacks can signal confidence in a company’s balance sheet and cash generation, but they also show where executives believe the best near-term use of capital sits. That matters in a pet market that’s maturing and becoming more selective: Morgan Stanley said in June 2026 that industry growth is slowing as costs rise, while veterinary services are taking a larger share of pet spending and remain one of the most resilient categories. In that environment, clinics, distributors, and suppliers may want to watch whether publicly traded partners continue prioritizing innovation, manufacturing, diagnostics, and service support at the same time they step up shareholder returns. (morganstanley.com)
What to watch: The next test is whether more pet and animal health companies add repurchase authorizations in upcoming earnings cycles, and whether those programs accelerate if valuations stay under pressure. (globalpetindustry.com)
Share buybacks are gaining ground in the pet sector as listed companies look for more flexible ways to reward investors. According to GlobalPETS’ analysis of 14 publicly traded pet-related businesses, dividends still dominate, but a growing number of companies are adding repurchase programs or expanding existing ones. The shift comes as pet companies face a more mature market, softer valuation multiples, and tougher questions about how to deploy cash. (globalpetindustry.com)
The backdrop is important. During the pandemic and its aftermath, many pet companies benefited from unusually strong demand, premiumization, and investor enthusiasm. That environment has cooled. Morgan Stanley said in June 2026 that pet industry growth is slowing as rising costs push consumers to spend more selectively, even though healthcare and veterinary services remain relatively resilient. GlobalPETS separately reported that valuation multiples for U.S. pet companies have fallen to multi-year lows, creating conditions where boards may see buybacks as an efficient use of capital when they believe the market is undervaluing their shares. (morganstanley.com)
Recent filings and company announcements show how that logic is playing out. Central Garden & Pet announced on February 17, 2026, that its board had added $100 million to its repurchase program, explicitly stating that management considered the share price undervalued. The program has no expiration date and allows purchases in the open market or through private transactions, including Rule 10b5-1 plans. Freshpet followed on May 21, 2026, with a $150 million authorization, with CFO John O’Connor saying the company’s balance sheet, free cash flow, and proceeds from the sale of its Ollie stake gave it room both to invest in the business and to repurchase stock when it traded below intrinsic value. Freshpet later disclosed that it had already repurchased about $54.4 million of shares during the quarter ended June 30, 2026, leaving about $95.6 million available under the program. (ir.central.com)
Zoetis offers a larger-scale example from animal health. The company announced a multi-year $6 billion share repurchase program in 2024, and its 2026 proxy said Zoetis returned more than $4 billion to shareholders in 2025 through dividends and opportunistic buybacks. At the same time, company leadership has continued to frame repurchases as one part of a balanced approach, with business investment still the first priority. At a June 2026 investor conference, management said dividends and buybacks are both important pillars, but that investing in products and unmet needs in animal health remains the primary focus. (investor.zoetis.com)
Expert and market commentary suggests the strategy has both supporters and skeptics. Supporters argue buybacks can be a disciplined way to return excess capital, especially when shares are depressed and internal or acquisition opportunities are less attractive. Critics, though, warn that boards can overestimate the value created by repurchases, particularly when buybacks mainly offset dilution from stock compensation or come at the expense of long-term investment. Harvard Business Review this year argued that many boards underestimate the real cash cost of buybacks used to neutralize dilution, underscoring why investors and industry watchers are paying closer attention to the quality of capital allocation, not just the headline dollar amount. (hbr.org)
Why it matters: For veterinary professionals, the buyback trend is less about Wall Street mechanics than about corporate priorities. Many veterinary practices depend on pet and animal health companies for pharmaceuticals, diagnostics, nutrition, preventive products, and client-facing support. If more public companies shift cash toward repurchases, the key question is whether they can still sustain R&D, field support, supply chain investment, and service innovation. That question is especially relevant now because veterinary care is taking a larger share of total pet spending, according to Morgan Stanley, making animal health and clinical services some of the most strategically important parts of the broader pet economy. (morganstanley.com)
There’s also a signal value here. When companies such as Central and Freshpet say their stock is undervalued, they’re not just returning cash, they’re making a public statement about confidence in future earnings and cash flow. For veterinary businesses, that can be a useful indicator of which suppliers feel financially strong enough to support both shareholder returns and ongoing investment. But the inverse is also true: if buybacks rise while product launches, service levels, or clinical support lag, veterinary teams may read that as a sign of short-term pressure. (ir.central.com)
What to watch: Watch upcoming earnings releases and proxy filings for new repurchase authorizations, actual dollars spent, and how management teams justify those decisions. The most important distinction for veterinary professionals will be whether buybacks are presented as truly excess-capital deployment, or as a substitute for growth investment in a slower, more cost-conscious pet market. (ir.central.com)